[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anavex Lf SC (AVXL)

Anavex Lf SC (AVXL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 303,964
  • Shares Outstanding, K 92,672
  • Annual Sales, $ 0 K
  • Annual Income, $ -46,380 K
  • EBIT $ -32 M
  • EBITDA $ -51 M
  • 60-Month Beta 1.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.26

Options Overview Details

View History
  • Implied Volatility 104.32% (+11.72%)
  • Historical Volatility 64.14%
  • IV Percentile 48%
  • IV Rank 8.50%
  • IV High 475.96% on 11/13/25
  • IV Low 69.80% on 04/08/26
  • Expected Move (DTE 13) 0.31 (9.42%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 164
  • Volume Avg (30-Day) 327
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 28,801
  • Open Int (30-Day) 29,599
  • Expected Range 3.03 to 3.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 1
  • High Estimate $-0.08
  • Low Estimate $-0.08
  • Prior Year $-0.16
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.26 +48.12%
on 07/17/26
3.40 -1.76%
on 08/07/26
+0.63 (+23.25%)
since 07/07/26
3-Month
2.26 +48.12%
on 07/17/26
3.40 -1.76%
on 08/07/26
+0.22 (+7.05%)
since 05/07/26
52-Week
2.26 +48.12%
on 07/17/26
11.70 -71.45%
on 08/12/25
-7.88 (-70.22%)
since 08/07/25

Most Recent Stories

More News
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation

Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz,  Who Bring Deep, Relevant Experience in Life Sciences Mr. Patel and Dr. Senderowicz to Stand for Election at...

AVXL : 3.34 (+1.83%)
Anavex Life Sciences: Fiscal Q2 Earnings Snapshot

Anavex Life Sciences: Fiscal Q2 Earnings Snapshot

AVXL : 3.34 (+1.83%)
Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for...

AVXL : 3.34 (+1.83%)
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments...

AVXL : 3.34 (+1.83%)
Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments...

AVXL : 3.34 (+1.83%)
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease

Findings underpin the scientific rationale for Anavex’s targeted autophagy approach with orally administered blarcamesine Convergence of impaired autophagy and synaptic dysfunction across neurodevelopmental...

AVXL : 3.34 (+1.83%)
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 3.34 (+1.83%)
Anavex Life Sciences Provides Comprehensive Regulatory Update

Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional data submitted to the U.S. FDA with the objective...

AVXL : 3.34 (+1.83%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are...

AVXL : 3.34 (+1.83%)
Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip?

Anavex shares crash as the EMA indicates it won’t issue a positive opinion on its candidate Alzheimer’s drug. Here’s why long-term investors may still consider loading up on AVXL stock today.

AVXL : 3.34 (+1.83%)

Business Summary

ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill...

See More

Key Turning Points

3rd Resistance Point 3.47
2nd Resistance Point 3.43
1st Resistance Point 3.39
Last Price 3.34
1st Support Level 3.31
2nd Support Level 3.27
3rd Support Level 3.23

See More

52-Week High 11.70
Fibonacci 61.8% 8.09
Fibonacci 50% 6.98
Fibonacci 38.2% 5.86
Last Price 3.34
52-Week Low 2.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.